First Time Loading...

Prescient Therapeutics Ltd
ASX:PTX

Watchlist Manager
Prescient Therapeutics Ltd Logo
Prescient Therapeutics Ltd
ASX:PTX
Watchlist
Price: 0.048 AUD -4% Market Closed
Updated: May 2, 2024

Prescient Therapeutics Ltd
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Prescient Therapeutics Ltd
Revenue Peer Comparison

Comparables:
IMM
MSB
CSL
CUV
TLX

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Prescient Therapeutics Ltd
ASX:PTX
Revenue
AU$697.9k
CAGR 3-Years
119%
CAGR 5-Years
47%
CAGR 10-Years
N/A
Immutep Ltd
ASX:IMM
Revenue
AU$256.6k
CAGR 3-Years
-61%
CAGR 5-Years
-45%
CAGR 10-Years
-24%
Mesoblast Ltd
ASX:MSB
Revenue
$7.5m
CAGR 3-Years
-23%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
CSL Ltd
ASX:CSL
Revenue
$14.2B
CAGR 3-Years
12%
CAGR 5-Years
11%
CAGR 10-Years
10%
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Revenue
AU$87.3m
CAGR 3-Years
31%
CAGR 5-Years
25%
CAGR 10-Years
42%
Telix Pharmaceuticals Ltd
ASX:TLX
Revenue
AU$502.5m
CAGR 3-Years
359%
CAGR 5-Years
381%
CAGR 10-Years
N/A

See Also

What is Prescient Therapeutics Ltd's Revenue?
Revenue
697.9k AUD

Based on the financial report for Dec 31, 2023, Prescient Therapeutics Ltd's Revenue amounts to 697.9k AUD.

What is Prescient Therapeutics Ltd's Revenue growth rate?
Revenue CAGR 5Y
47%

Over the last year, the Revenue growth was 317%. The average annual Revenue growth rates for Prescient Therapeutics Ltd have been 119% over the past three years , 47% over the past five years .